EUROPE – Biogen has withdrawn its application for the Alzheimer’s disease drug in the European Union after discussions with regulators revealed that the data provided thus far is unlikely to…
Read MoreTag: Alzheimer’s disease
Fujifilm develops artificial intelligence tech for predicting Alzheimer’s progression
JAPAN – Fujifilm Corporation has developed artificial intelligence technology that can predict whether patients with mild cognitive impairment will develop Alzheimer’s disease (AD) within two years. According to a press…
Read MoreMedicare finalizes restrictions on Biogen Alzheimer’s drug
USA – Medicare will not pay for Biogen’s new Alzheimer’s drug unless prospective patients are enrolled in a clinical trial, the US government has announced, severely limiting the drug’s use.…
Read MoreBiogen begins downsizing staff following disastrous debut of its Alzheimer’s drug
USA – Biogen has begun to lay off employees as part of a previously announced effort to cut annual expenses by US$500 million. The move comes as the Cambridge, Massachusetts-based…
Read MoreLilly slacks off FDA submission of Alzheimer’s drug after CMS decision on Aduhelm
USA – Eli Lilly has pushed back the deadline for submitting an application for U.S. approval of its experimental Alzheimer’s disease drug, revealing that it will now complete the filing…
Read MoreMore Federal regulators launch probe into Biogen’s Aduhelm
USA – The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have opened separate investigations into Biogen Inc and its Alzheimer’s medication, Aduhelm (aducanumab). According to the…
Read MoreTakeda, Denali’s Alzheimer’s candidate drug hits regulatory drawback
USA – The FDA has placed a clinical hold on Denali Therapeutics’ Alzheimer’s drug before it even enters human trials. The decision has an impact on Takeda, which only recently…
Read MoreGSK takes aim at CNS diseases with University of Oxford partnership
UNITED KINGDOM – GSK and Oxford have launched a five-year collaboration aimed at accelerating R&D breakthroughs in a variety of difficult-to-treat diseases such as Alzheimer’s and Parkinson’s through the use…
Read MoreNovartis pays US$150 million to gain rights to UCB’s Parkinson’s drug
BELGIUM – Novartis is putting US$150 million into a Parkinson’s disease drug candidate that is competing with drugs in development at companies such as Roche and AstraZeneca. Novartis will pay…
Read MoreFirst nasal vaccine against Alzheimer’s disease enters human trial phase
USA – Clinical trial for Alzheimer’s disease (AD) nasal vaccine has been launched to see whether a potential treatment could be safe for humans after the therapy showed positive results…
Read More